Article
HSV1716 persistence in primary human glioma cells in vitro.
Gene therapy - 1 Sept 2002
Harland J, Papanastassiou V, Brown S M
Abstract excerpt
HSV1716 is a selectively replication competent mutant of herpes simplex virus which is in trial in glioma patients. We have demonstrated that HSV1716 is non-toxic when delivered into tumour or into brain adjacent to tumour, yet replicates within tumour cells. Tumour tissue, from one patient treated 2.5 years previously with intra-tumoural HSV1716, was put into culture. The cultured cells were shown to be glial in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
